Loading organizations...
§ Private Profile · Zwingenberg, Hessen, Germany
biotechnology company developing RNA-guided cell depletion therapies using G-dase® E nucleases to selectively target cancer cells.
Akribion Therapeutics is a Zwingenberg, Germany-based biotechnology company that develops RNA-guided, programmable cell depletion therapies for precision oncology. The organization utilizes its proprietary G-dase E CRISPR-Cas nuclease platform to selectively target and destroy cancer cells based on specific RNA biomarkers, eliminating diseased cells while sparing healthy tissue. Operating as an independent spin-off, the enterprise recently exited stealth mode after securing €8 million in seed financing to advance its preclinical research and development pipeline. This initial seed funding round was jointly led by venture capital firms CARMA FUND and RV Invest, with additional equity participation from High-Tech Gründerfonds. Additionally, the firm signed an exclusive pharmaceutical license agreement with its former parent company, BRAIN Biotech, to commercialize these novel gene-editing discoveries across broader medical applications. Akribion Therapeutics was officially founded in 2024 by Dr. Michael Krohn and Lukas Linnig.
Akribion Therapeutics has raised $9.3M across 1 funding round.
Akribion Therapeutics has raised $9.3M in total across 1 funding round.
Akribion Therapeutics has raised $9.3M in total across 1 funding round.
Akribion Therapeutics's investors include Carma Fund, RV Invest.
Akribion Therapeutics has raised $9.3M across 1 funding round. Most recently, it raised $9.3M Seed in February 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 4, 2025 | $9.3M Seed | Carma Fund, RV Invest | — | Announced |